金融事业部 搜狐证券 |独家推出
买入研报查询: 按股票 按研究员 按机构 高级查询 意见反馈
首页 上页 下页 末页 1/1 转到  

最新买入评级

研究员 推荐股票 所属行业 起评日* 起评价* 目标价 目标空间
(相对现价)
20日短线评测 60日中线评测 推荐
理由
发布机构
最高价* 最高涨幅 结果 最高价* 最高涨幅 结果
通化东宝 医药生物 2016-08-24 22.86 17.72 68.76% 22.99 0.57%
24.32 6.39%
详细
H1results in line with expectations H1revenue/net profit excluding one-offs jumped 14.1%/36%, matching expectations.We think the insulin market has significant potential and that Dongbao has a clearadvantage in the primary market. We see a five-year revenue CAGR of 20%+ forDongbao, as the online platform could further increase doctor/patient engagement and3rd-gen insulin could get approved. We think profit growth will outpace revenuegrowth on economies of scale. With dilution from a private placement factored in,Dongbao is trading at 43x 2017E PE, in line with its historical average. We thinkvaluation still has room to rise as 3rd-gen insulin registration progresses steadily. Insulin bucked the trend and maintained rapid growth Revenue from insulin preparations increased 19% YoY in H1. Revenue in the insulinsegment rose only 15.2%, hit by a c50% decline in exports. Since Q2, the governmenthas strengthened its supervision over distribution, causing some small distributors todestock. The destocking has not yet ended, so we slightly cut our insulin revenueforecast for full-year 2016. Insulin gross margin expanded 3.5% YoY to 87.4% butDongbao said it sees little room for further growth. The selling expense ratio decreased4.2% YoY to 23.2%. Even considering that big events are largely concentrated in H2,the full-year selling expense ratio could still be much lower YoY. Blood glucose monitoring/online platform/3rd-gen insulin progress smoothly Having taken over Bionime's distributors, Dongbao is expanding equipment sales tomore hospitals. Dongbao's plan to add 1k hospitals this year (completed 400+ in H1)and 3k within three years could drive rapid equipment revenue growth. The rising shareof self-operated outlets could boost equipment sales gross margin. Dongbao's onlineplatform, which is under beta testing with c100,000/1,000+ patient-/doctor-users, maygo online in September. The platform mainly helps doctors manage their patients, witha low cost of bringing in users. Dongbao plans to apply for insulin glargine productionin H2. Insulin aspart completed a clinical trial in July and is undergoing data cleansing,with plans to apply for production in 2017. Further, Dongbao has begun to developantidiabetic drugs other than insulin. Valuation: Raising DCF-based PT to Rmb26.30, implying 49x 2017E PE Our new DCF-based PT is Rmb26.30(WACC 6.2%). Major changes: 1) slightly cut2017/18E earnings; 2) raise 3rd-gen insulin's chance of approval to 90% from 75%; 3)roll over valuation to end-2017; and 4) slight EPS dilution post private placement.
首页 上页 下页 末页 1/1 转到  
*说明:

1、“起评日”指研报发布后的第一个交易日;“起评价”指研报发布当日的开盘价;“最高价”指从起评日开始,评测期内的最高价。
2、以“起评价”为基准,20日内最高价涨幅超过10%,为短线评测成功;60日内最高价涨幅超过20%,为中线评测成功。详细规则>>
3、 1短线成功数排名 1中线成功数排名 1短线成功率排名 1中线成功率排名